GX-P1 / Genexine, GenNBio, Egret - LARVOL DELTA

Safety and Tolerability of GX-P1 in Healthy Male Volunteers (clinicaltrials.gov) - P1; N=24; Completed; Sponsor: Genexine, Inc.; Recruiting ➔ Completed

Trial completion • Immunology

Turret Capital announces a global in-licensing agreement with Genexine (PRNewswire) - “Turret Capital Management…announced today that it has signed a Definitive License Agreement with Genexine, inc… Under the terms of the agreement, Turret Capital has obtained global rights for selective indications to GX-P1….Under the terms of the agreement, Genexine will receive 5% of underlying Egret Therapeutics outstanding shares and be eligible to receive development and commercial milestones payments of up to $200 million USD.”

Licensing / partnership • Oncology

Genexine inks deal to license out novel immunosuppressant agent to Turret Capital (Pulse by Maeil Business News Korea) - "Genexine shares gained nearly 15 percent Thursday morning upon news that the Korean biotech firm entered an agreement to license out its single-agent immune checkpoint inhibitor GX-P1 to U.S. healthcare-focused investment and venture building firm Turret Capital....Under the agreement, Genexine will receive 1 million shares or 5 percent of Egret Therapeutics’ total outstanding shares as a down payment. Genexine is also eligible to receive additional payments in development and commercial milestones from $200 million to $1.5 billion when the drug is sub-licensed."

Commercial • Licensing / partnership • Oncology

Safety and Tolerability of GX-P1 in Healthy Male Volunteers (clinicaltrials.gov) - P1; N=32; Recruiting; Sponsor: Genexine, Inc.; Not yet recruiting ➔ Recruiting; Initiation date: Apr 2020 ➔ Aug 2020; Trial primary completion date: Mar 2021 ➔ Aug 2021

Clinical • Enrollment open • Trial initiation date • Trial primary completion date • Immunology

Safety and Tolerability of GX-P1 in Healthy Male Volunteers (clinicaltrials.gov) - P1; N=32; Not yet recruiting; Sponsor: Genexine, Inc.

Clinical • New P1 trial